Xiapex regulatory update

Germany's Federal Joint Committee (G-BA) issued a final assessment that found no additional benefit for Dupuytren's contracture drug Xiapex collagenase clostridium histolyticum because the dossier submitted by Pfizer Inc. (NYSE:PFE, New York, N.Y.) was incomplete. The assessment is in line with a February preliminary assessment from Institute for Quality and Efficiency in Health Care (IQWiG). Xiapex will be added to the reference pricing system; Pfizer will not be able to negotiate (see BioCentury, Feb. 6). ...